Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.

Byrd, J C; Waselenko, J K; Maneatis, T J; Murphy, T; Ward, F T; Monahan, B P; Sipe, M A; Donegan, S; White, C A

Byrd, J C; Waselenko, J K; Maneatis, T J; Murphy, T; Ward, F T; Monahan, B P; Sipe, M A; Donegan, S; White, C A.

Affiliation

Byrd JC; Division of Hematology-Oncology, Walter Reed Army Medical Center, Washington, DC 20307, USA. john_c.byrd@wramaa.chcs.amedd.army.mil

J Clin Oncol ; 17(3): 791-5, 1999 Mar.

Article in En | MEDLINE | ID: mdl-10071268

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Lymphoma, Large B-Cell, Diffuse / Antibodies, Monoclonal / Neoplastic Cells, Circulating / Antineoplastic Agents Type of study: Etiology_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 1999 Document type: Article Affiliation country:

Search on Google

Add to My VHL

XML

PubMed Links